Please assess the completion status of the following clinical trial:

Trial Title: Psilocybin for the Treatment of Cluster Headache

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic cluster headache with at least one attack daily~* Episodic cluster headache with periods that are predictable and have a duration of approximately 2 months~* Attacks are managed by means involving no more than twice weekly triptan use (e.g., high-flow oxygen, heat/cold pack)~Exclusion Criteria:~* Axis I psychotic disorder (e.g. schizophrenia, bipolar I, depression with psychosis)~* Axis I psychotic disorder in first degree relative~* Unstable medical condition, severe renal, cardiac or hepatic disease, pacemaker, or serious central nervous system pathology~* Pregnant, breastfeeding, lack of adequate birth control~* History of intolerance to psilocybin, lysergic acid diethylamide (LSD), or related compounds~* Drug or alcohol abuse within the past 3 months (excluding tobacco)~* Urine toxicology positive to drugs of abuse~* Use of vasoconstrictive medications (i.e. sumatriptan, pseudoephedrine, midodrine) within five half-lives of test days~* Use of serotonergic antiemetics (i.e. ondansetron) in the past 2 weeks~* Use of antidepressant medications (i.e. amitriptyline, isocarboxazid, fluoxetine, citalopram) in the past 6 weeks~* Use of steroids or certain other immunomodulatory agents (i.e. azathioprine) in the past 2 weeks

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Psilocybin High Dose (Type: ACTIVE_COMPARATOR): None
- Psilocybin Low Dose (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).